RxDoctor Payments Data

Charles Stanich, MD

Internal Medicine · Gulfport, MSNPI 1356424576

Payments from drug & device makers

$1,899in general payments, 2019–2025

Across 114 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$422
  • Johnson & Johnson$411
  • Novartis$225
  • UCB, Inc.$205
  • Lexicon Pharmaceuticals, Inc.$126
  • Mallinckrodt Hospital Products Inc.$81
  • plus $429 from 14 others

What the payments were for

  • Food & beverage$1,85998%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,899 in reported general payments places this provider in the 70th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$370,130
Medicare patients
746
Services billed
3,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$44,569
NuedextaDextromethorphan Hbr/Quinidine23$17,481
RexultiBrexpiprazole18$9,852
Breo ElliptaFluticasone/Vilanterol20$8,430
EntrestoSacubitril/Valsartan17$7,744
LinzessLinaclotide11$6,200
NamzaricMemantine Hcl/Donepezil Hcl14$4,125
NovologInsulin Aspart37$3,150
Divalproex Sodium91$3,127
MyrbetriqMirabegron12$2,710
Pantoprazole Sodium115$2,696
Rivastigmine13$2,454
Nefazodone Hcl24$2,224
LantusInsulin Glargine,hum.Rec.Anlog31$2,197
Potassium Chloride123$1,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$422$44,569150 claims
Avanir Pharmaceuticals, Inc.Nuedexta$14$17,48123 claims
AbbVieLinzess, Namzaric$49$10,32525 claims
Otsuka America Pharmaceutical, Inc.Rexulti$40$9,85218 claims
NovartisEntresto$225$7,74417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →